

# How Long Term Outcomes Have Changed Our Approach in the Management of Patients with Spina Bifida

Mark P. Cain, MD, FAAP

Robert Garrett Professor

Chief Of Pediatric Urology

Riley Hospital for Children at IU Health




Riley Hospital for Children  
Indiana University Health

I have no financial disclosures.




I

# Problem: Med/Surgical and Social





# VUR and Bladder Pressure = Renal Disaster





# Spina Bifida - Urologic Management


## Options for Intervention

- **Bladder Relaxants**
- **Clean Intermittent Catheterization**
- Urethral Overdilation
- Botox Injection
- Nocturnal Bladder Drainage
- Bladder Electrical Stimulation
- Sacral Spinal Cord Stimulation
- Vesicostomy
- **Bladder Reconstructive Surgery**

# Management of Neuropathic Bladder and Bowel: Historical Surgical Pathway to Continence

Evolution of continence:



- Intermittent catheterization
  - Bladder outlet resistance
  - Bladder augmentation
- 
- Mitrofanoff procedure
  - MACE procedure





# BLADDER AUGMENTATION

## ERA OF RECONSTRUCTION



# Historical Evaluation of Incontinence and Surgical Results

- Surgeon driven
- Surgeon evaluated
- Parents as proxy for children's outcome
- No validated, disease specific surveys
- No long term follow up into teen/adult life
- Outcomes based on "Pad or diaper use", dry interval (3-4 hours), didn't separate "moving parts" of complex operations



# Pediatric Urology at Indiana University

## Bowel In LUR : Indiana

**1978 – 2018**

**40 Years**

**12 Surgeons**

**>75 Journal articles**

**>20 Chapters**

**~ 800 Augments**

**> 900 Cath Chan.**

**Rick Rink, MD, FAAP, FACS**

**Mark Cain, MD, FAAP**

**Martin Kaefer, MD, FAAP**

**Rosalia Misseri, MD, FAAP**

**Ben Whittam, MD, MS**

**Kate Hubert, MD, MPH**

**Konrad Szymanski, MD, MPH**

**Shelly King, CNP**

**Melissa Young, CNP**

**Hillary Risk, CNP**

**Taylor Wang, CNP**

**Bob Garrett, MD, Mike Mitchell, MD, Mike Keating, MD,  
Mark Adams, MD, Tony Casale, MD, Kirstan Meldrum, MD**


# One Surgeon's View On:

- Why large databases are important.....
- Why long term follow up is important in decision making for childhood diseases.....
- Why we need to ask our patients what they want at sequential times over their young lives.....
- Why we need to think differently about health care delivery for chronic and congenital diseases.....




# Bladder Complications: Indy 500

The Need for Additional Bladder Surgery After Augmentation



**Metcalfe et al  
JUrol, 2006**

# Survival in the Era of Aggressive Bladder Management



## Mortality after Bladder Augmentation in Children with Spina Bifida

Konrad M. Szymanski,\* Rosalia Misseri, Benjamin Whittam, Cyrus M. Adams, Jordan Kirkegaard, Shelly King,† Martin Kaefer, Richard C. Rink and Mark P. Cain

From the Division of Pediatric Urology, Riley Hospital for Children at IU Health, Indianapolis, Indiana



# Causes of death

- Non-adherence with CIC
- Pre-existing renal insufficiency

Cause of death	Total (n=28)
Infection	16
<i>Ventriculoperitoneal/atrial shunt-related infection</i>	7
<i>Decubitus ulcer fasciitis</i>	2
<i>Peritonitis</i>	2
<i>Urosepsis</i> →	2
<i>Pneumonia</i>	1
<i>Sepsis (unknown source)</i>	2
Non-infectious pulmonary	3
Congenital cardiac disease	2
Renal failure →	2
Ventriculopleural shunt obstruction	1
Iatrogenic cardiac tamponade	1
Motor vehicle collision	1
Suicide	1
Unknown	1

# We Are All Victims of Our Survival

- 14<sup>th</sup> Century – 30% of population died of plague
- 1900s - Pre ABX, Vaccines, Sanitation
  - Infection (pneumonia), TB, GI infections
- 1990 – Modern medicine era
  - MI, CA, Stroke (60%), COPD, Dementia\*
- 2018 - prevention + gene therapy
- Spina Bifida patients (and us) now living longer
- Quality of Life matters more, especially later.....





**Indications  
Different**

**Does Surgery  
Matter?**



**Does Continence  
Matter?**



# Urologic Management

## GOALS OF INTERVENTION:

Renal

Bladder

Prevent Infection

Urinary/Fecal Continence

Transition to Independent Care

QUALITY OF LIFE...

**Don't turn a social problem into a medical problem....**

# Health Related Benefit after Reconstruction for Urinary/Fecal Incontinence in Children: Parent Perspective

- 300 families evaluated, 120 responses
- Glasgow Inventory (validated) + 6 specific questions
- Statistically significant improved HRB
- What changed life most:
  - 31% MACE, 44% aug/channel, 25% both
- What did parents find most important:
  - 48% stool continence
- 68% needed less/no assistance with care

**Strine, Misseri et al, J Urol, 2015**

## A Piece of My Mind

April 17, 2018

# Mentoring Millennials

Jennifer F. Waljee, MD, MPH, MS<sup>1</sup>; Vineet Chopra, MD, MSc<sup>2</sup>; Sanjay Saint, MD, MPH<sup>3</sup>

» [Author Affiliations](#) | [Article Information](#)

JAMA. 2018;319(15):1547-1548. doi:10.1001/jama.2018.3804

Millennials have been shaped by a profound expansion of information technology, enhanced social networking, and a connected global culture. Although sometimes labeled as impatient, distracted, overly socialized, and entitled, millennials could also be characterized as deeply empowered, collaborative, and innovative. These generalizations, however, can lead to conflict and misunderstanding, particularly in environments such as hospitals where apprenticeship and hierarchy are the norm.

Mentorship is the cornerstone of academic medicine. A mentor is defined as an advisor characterized by altruism, expertise, patience, and experience. In many ways, graduate medical education has adapted to millennials through the expansion of online and video-based learning resources, disease-based educational curricula, abbreviated work hours, and team-based care models.<sup>2</sup> However, mentorship strategies for millennial faculty members, residents, and medical students are not well understood. Indeed, we have personally witnessed generational differences leading to frustration, miscommunication, and attrition in these mentor-mentee dyads. Consider 3 common scenarios.



# Riley Pediatric Urology Team 2018



# Does urinary incontinence affect HRQOL in adults with SB?

- Two studies report no difference<sup>1,2</sup>
  - Only measured dry interval
  - Did not use SB-specific questionnaire
- Adults with SB recruited online and clinic
  - Daytime UI (dry interval, quantity, undergarments)
  - SB-specific HRQOL (QUALAS-A<sup>3</sup>)

1. Lemelle, J. L., Guillemin, F., Aubert, D. et al.: Quality of life and continence in patients with spina bifida. *Qual Life Res*, 15: 1481, 2006

2. Vu Minh Arnell, M., Seljee Svedberg, K., Lindehall, B. et al.: Health-related quality of life compared to life situation and incontinence in adults with myelomeningocele: is SF-36 a reliable tool? *J Pediatr Urol*, 9: 559, 2013


3. Szymanski, K. M., Misseri, R., Whittam, B. et al.: QUALity of Life Assessment in Spina bifida for Adults (QUALAS-A): development and international validation of a novel health-related quality of life instrument. *Qual Life Res*, 2015

# Population characteristics (n=518 Adults; 150 Adolescents; 250 Kids) Validated for each age group

Median age: 31.9 years (78.7% live in US)




# HRQOL and urinary incontinence: Does It Matter to Adult Spina Bifida Patients?



Szymanski et al, AUA/JUrol, 2016



# Does Urinary/Fecal Incontinence Matter to Adult Spina Bifida Patients?



# HAVE WE HELPED CHILDREN?

## Quality of life

*QUALity of Life Assessment in Spina bifida for Adults (QUALAS-A): development and international validation of a novel health-related quality of life instrument*

**Konrad M. Szymanski, Rosalia Misseri, Benjamin Whittam, Sonia-Maria Raposo, Shelly J. King, Martin Kaefer, Richard C. Rink, et al.**

**Quality of Life Research**  
An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation - Official Journal of the International Society of Quality of Life Research

ISSN 0962-9343  
Volume 24  
Number 10

Qual Life Res (2015) 24:2355-2364  
DOI 10.1007/s11136-015-0988-5



 Springer

Pediatric Urology

### Quality of Life Assessment in Spina Bifida for Children (QUALAS-C): Development and Validation of a Novel Health-related Quality of Life Instrument



**Konrad M. Szymanski, Rosalia Misseri, Benjamin Whittam, David Y. Yang, Sonia-Maria Raposo, Shelly J. King, Martin Kaefer, Richard C. Rink, and Mark P. Cain**

<b>OBJECTIVE</b>	To develop and validate a self-reported health-related QUALity of Life Assessment in Spina bifida for Children (QUALAS-C).
<b>METHODS</b>	We drafted a 27-question pilot instrument using a patient-centered comprehensive item generation and refinement process. It was administered to a sample of children 8-12 years old with spina bifida (SB) recruited online via social media and in person at an outpatient SB clinic (January 2013-September 2014). Healthy controls were recruited at routine pediatrician visits. Validation and final questions were determined based on clinical relevance, high loadings on factor analysis, and domain psychometrics. Children with SB also completed the validated generic Kidscreen-27 instrument.
<b>RESULTS</b>	Median age of 150 participants was 9.6 years (60.7% male, 72.7% Caucasian), similar to 46 controls ( $P \geq .10$ ). There were 97 online and 53 clinic participants (89.0% and 84.2% of eligible, respectively). Face and content validities of the 2-domain, 10-question QUALAS-C were established by patients, parents, and experts. Internal consistency and test-retest reliability was high for the Esteem & Independence and Bladder & Bowel domains (Cronbach's alpha: 0.72-0.76, ICC: 0.74-0.77). Correlations between QUALAS-C domains were low ( $r = 0.51$ ), indicating that QUALAS-C can differentiate between two distinct health-related quality of life components. Correlations between QUALAS-C and Kidscreen-27 were also low ( $r \leq 0.44$ ). QUALAS-C scores were significantly lower in children with SB than without ( $P < .0001$ ).
<b>CONCLUSION</b>	QUALAS-C is a short, valid health-related quality of life tool for children with SB. It will be useful in clinical and research settings. UROLOGY 87: 178-184, 2016. © 2015 Elsevier Inc.

Spina bifida (SB) is the most common congenital anomaly of the central nervous system, affecting 3.4 per 10,000 live births in the United States.<sup>1</sup> Children surviving infancy face neurological, neurosurgical, orthopedic, and urological challenges. Unfortunately, studies on health-related quality of life (HRQOL) in children with SB tend to be small, single-institutional studies using limited, poorly-validated, or non-validated, instruments.<sup>2-6</sup> Others

report patient satisfaction, rather than HRQOL.<sup>7,8</sup> Importantly, generic HRQOL instruments developed for healthy children<sup>9,10</sup> may be unable to capture small, but clinically important, differences because they were not designed to measure the impact of SB on HRQOL.<sup>11</sup> Moreover, no validated and comprehensive SB-specific HRQOL instrument exists which incorporates bladder and bowel domains.

SB-specific HRQOL is a component of quality of life that focuses on an individual's perception of the impact of SB on his/her physical and psychosocial functioning.<sup>11,12</sup> Assessing self-reported HRQOL is particularly important, as those with SB often report better HRQOL than perceived by their parents and caregivers.<sup>13,14</sup> For this reason, instrument development requires input from individuals with SB, their parents, and caregivers.<sup>2,11</sup> An ideal, clinically relevant HRQOL instrument focuses on HRQOL rather than physical function. It should also possess excellent psychometric properties and be condition specific, yet remain short

**Financial Disclosure:** The authors declare that they have no relevant financial interests.


**Funding Support:** Funding was provided by the Indiana University School of Medicine's Department of Urology.

From the Division of Pediatric Urology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN

Address correspondence to: Konrad M. Szymanski, M.D., M.P.H., Division of Pediatric Urology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, 705 Riley Hospital Dr. #4230, Indianapolis, IN 46205. E-mail: szymanski@iupui.edu

Submitted: August 6, 2015, accepted (with revisions): September 21, 2015

# Does Incontinence Matter at Different Ages



Szymanski  
et al, 2017

# Quality of Life is Just as Important for Kids as End of Life for Adults

#1 NEW YORK TIMES BESTSELLER

Atul Gawande



Being Mortal

Medicine and What Matters in the End




# I Didn't Always Think About My Patients As Eventual (Sexual) Adults..... But They Will Be



# IU Research Regarding Sexuality

International anonymous online survey  
Men and women 18+ years old with SB who spoke English  
(2016-2017)

Recruitment:  
SB clinics  
Online via social media



If you are an adult with **spina bifida**,  
we want to hear from you!

Researchers at Indiana University School of Medicine are interested in learning more about the sexual health of adults with spina bifida.

If you are 18 or older and have spina bifida, you can participate, whether or not you ever had sex. We will ask questions about your background, your experiences with spina bifida, and your sexuality (feelings about sex, sexual behaviors, and desires for a family). It takes only 15-20 minutes.

All your answers are confidential and completely anonymous. No one you know will see your answers. Even the researchers will not be able to identify who you are or your answers. Thank you!

To go to the survey, go to this link:

<https://goo.gl/NocVRR>

or scan this code:



# Relationships

<b>Single</b>	<b>50.7%</b>
<b>In relationship</b>	<b>47.8%</b>
<b>Dating, hanging out</b>	<b>4.4%</b>
<b>Dating, in a relationship</b>	<b>14.5%</b>
<b>Living together, not married</b>	<b>10.1%</b>
<b>Married</b>	<b>18.8%</b>
<b>Divorced, separated</b>	<b>1.5%</b>

# **Lifetime sexual activities (ever events)**

<b>Masturbation alone</b>	<b>91.3%</b>
<b>Partnered non-genital contact (Cuddled, kissed, held hands)</b>	<b>85.5%</b>
<b>Partnered genital contact:</b>	
<b>Mutual masturbation</b>	<b>78.3%</b>
<b>Partnered intercourse</b>	<b>75.4%</b>
<b>Vaginal / anal</b>	<b>62.3% / 34.8%</b>



# Conclusions

**Partnered sexual activity common**

**May not involve penetrative intercourse**

**Better ambulatory status associated with better sexual outcomes and erectile function**

**ED is common in men with SB**

**PDE5Is are used frequently**

**May benefit this population**

# Urinary and Fecal Incontinence During Sexual Activity Is Common and Bothersome Among Adults with Spina Bifida

Joshua D. Roth, Devon J. Hensel, John S. Weiner, Rosalia Misseri,  
Konrad M. Szymanski



SCHOOL OF MEDICINE

INDIANA UNIVERSITY



Riley Hospital for Children  
Indiana University Health



Duke Medicine

# Baseline Data

## Baseline Incontinence in last 4 Weeks

**UI 66.7%**

**FI 50.7%**

## Bladder Management

## Stool Management

**CIC 44.6%**

**MACE 17.1%**

**Urostomy 6.8%**

**Colostomy 1.1%**

# Adults Without Diversion

**UI during Sex (64.6%) > FI/S (45.2%)** **p<0.001**

**UI during Sex**

**Women > men (76.0% vs. 52.2%)** **p=0.002**


**Greater with underlying UI (79.0% v. 48.7%)** **p=0.02**

**Not associated with age, shunt, ambulation, CIC** **p≥0.32**




# Adults Without Diversion

Level of Bother of Urinary Incontinence During Sexual Activity




# Adults Without Colostomy

## Frequency of Fecal Incontinence During Sexual Activity



# Adults Without Colostomy

## Level of Bother of Fecal Incontinence During Sexual Activity



# Conclusions

**Incontinence during sexual activity is a common problem for adults with SB**

**Baseline incontinence is an independent, but not absolute predictor of UIS and FIS**

**Women are more likely than men to experience UIS, regardless of baseline incontinence**






Kayce\_A\_riley\_fashion\_show204.JPG\_514c6201832d452994f1a6c0d2ff56b0V - Win



**Continence:  
For QOL,  
It Matters...**


# Quality of Life Conclusions: Reconstruction for Continence Matters (Still need Pre/Post Op Longitudinal Study)

- Intermittent catheterization
- Bladder outlet resistance
- Bladder augmentation
- Mitrofanoff procedure
- MACE procedure




# Bladder Complications: Indy 500

The Need for Additional Bladder Surgery After Augmentation



# Update on Bladder Complications: Indy 500

The Need for Additional Bladder Surgery After Augmentation





# **Additional surgeries after bladder augmentation in patients with spina bifida in the 21<sup>st</sup> century**

**Konrad Szymanski, Rosalia Misseri, Benjamin Whittam,  
Nathan Hollowell, Rachel Hardacker, Carly Swenson,  
Martin Kaefer, Richard Rink, Mark Cain**



**SCHOOL OF MEDICINE**

**INDIANA UNIVERSITY**



**Riley Hospital for Children**  
Indiana University Health

# Methods

**Retrospective cohort study of consecutive SB patients after bladder augmentation: 1978-2018**

**\*born after Jan. 1, 1972**

**Two cohorts:**

- 1. Entire group**
- 2. Modern (ileocystoplasty since 2000)**

**Risk factor: Detubularization & reconfiguration (DR)**

# Methods

<b>Outcomes:</b>	<b>Incontinent urinary diversion</b> <b>Bladder stones</b> <b>Bladder perforation</b> <b>Reaugmentation</b> <b>Laparotomy for bowel obstruction</b> <b>Bladder tumors (benign and malignant)</b>
<b>Statistics:</b>	<b>Survival analysis, Cox regression</b>

# Patient Selection

**Augmentation database: 784**

**Born before 1972: - 116**

**Not SB: - 255**

---

**Included in the study: 413**

# Population characteristics (n=413)

**Median age:** 8.5 years

**MMC:** 95.4%

**Segment: Ileum:** 80.9%

**Sigmoid:** 11.1%

**Urinary channel:** 74.1%

**MACE:** 69.1%



# Results

At median follow-up of 11.2 years  
**44.1% had 370 additional surgeries**

**\*34.6% were recurrences of the same secondary surgery**

**#1. Bladder stones (57.6% of all surgeries)**


**#2. Bladder perforation**

# Risk of any subsequent surgery

**5 years 25.5%**  
**10 years 43.9%**  
**20 years 57.4%**

**> 1 surgery at 10yr**

**2 or more 17.4%**  
**3 or more 9.9%**  
**4 or more 3.8%**




# Urinary diversion

**10 year risk 2.7%**  
**65.2% ileal conduit**

## Indications

**Perforations 34.8%**  
**Incontinence 34.8%**  
**UT changes 30.4%**  
**Difficult cath. 8.7%**



Number at risk		0	10	20	30	40
recon = 0	57	41	24	7	0	0
recon = 1	356	195	45	4	0	0

# Bladder stones


**10 year risk 28.2%**

**Endoscopic 32.5%**

**Percutaneous 29.9%**


**Open 37.6%**

**10 year recurrence  
52.4%**




# BLADDER STONES

## IU Experience: Removal Technique



**Endoscopic 32.7%**

**OPEN  
cytolithotomy  
33.6%**




**Percutaneous 33.6%**

**47.7 % had stone fragmented**



# Stone fragmentation



Number at risk:

Not fragmented 46

Fragmented 51

23

23

9

10

1

4

1

3

0

0

— Not fragmented — Fragmented

# Bladder perforation

## 10 year risk

Not DR 23.7%

DR 9.6%


**p=0.01**

## 10 year recurrence

Not DR 73.8%

DR 32.1%

**p=0.05**



# Reaugmentation

## 10 year risk

Not DR 15.2%

DR 5.3%


**p=0.001**

## Indications

Contractions 61.5%

Small capacity 53.8%

Incontinence 50.0%




Number at risk		0	10	20	30	40
recon = 0	57	41	24	7	0	0
recon = 1	356	195	45	4	0	0

# Laparotomy for bowel obstruction

**10 year risk 4.5%**

**91.3% small bowel**

**10 year recurrence  
10.0%**




# Excision of benign bladder tumor

**10 year risk 2.2%**

**100.0% nephrogenic adenoma**

**10 year regrowth 48.2%**





# **Bladder cancer**

**20 year risk 0.0%**

**No patient was diagnosed with  
bladder malignancy**

**\*\*we have 4 CA in database**

# Modern cohort (n=222)

## Ileocystoplasty since 2000

<u>Surgery</u>	<u>10 year risk</u>	<u>10 year recurrence</u>
Urinary diversion	4.0%	
Bladder stone	32.9%	44.5%
Bladder perforation	8.8%	42.2%
Reaugmentation	4.3%	
Bowel obstruction	4.9%	10.0%
Benign tumor excision	4.7%	40.0%
Bladder cancer	0.0%	


# Modern cohort (n=222) Ileocystoplasty since 2000

<u>Surgery</u>	<u>10 year risk</u>	<u>10 year recurrence</u>
Urinary diversion	4.0%	
Bladder stone	32.9%	44.5%
Bladder perforation	8.8%	42.2%
Reaugmentation	4.3%	
Bowel obstruction	4.9%	10.0%
Benign tumor excision	4.7%	40.0%
Bladder cancer	0.0%	


# Update on Bladder Complications:

The Need for Additional Bladder Surgery After Augmentation

Current View, 2018




# APPENDICOVESICOSTOMY





# Catheterizable Channels: Complications

- Stomal Stenosis
- Angulation of Channel
- Leakage
- Trauma
- Obliteration
- Abscess
- Polyp



**Short, Straight  
Supple, Secure**

# APPENDICOVESICOSTOMY VS. MONTI-YANG





# Appendicovesicostomy vs. Monti

0022-5347/99/1625-1749/0

THE JOURNAL OF UROLOGY

Copyright © 1999 by AMERICAN UROLOGICAL ASSOCIATION, INC.

Vol. 162, 1749–1752, November 1999

Printed in U.S.A.

## APPENDICOVESICOSTOMY AND NEWER ALTERNATIVES FOR THE MITROFANOFF PROCEDURE: RESULTS IN THE LAST 100 PATIENTS AT RILEY CHILDREN'S HOSPITAL

MARK P. CAIN, ANTHONY J. CASALE, SHELLY J. KING AND RICHARD C. RINK

*From the Department of Urology, James Whitcomb Riley Hospital for Children, Indiana University Medical Center, Indianapolis, Indiana*

**100 pts. : 57 Apv, 21 Monti, 21 CV**

**- 98% continence, 12% stomal stenosis**

**- 20 secondary procedures**


**12/57 Apv (21%) F/U 31 mos**

**2/21 Monti (10%) F/U 9 mos**

# Subfascial Revisions: Szymanski, J Ped Urol, 2015

Channel type and stomal location	Number	Number of first subfascial revisions	P-value	Median follow-up (years)
<b>APV</b>	<b>215</b>			
Non-umbilical	118	6 (5.1%)	reference	5.4
Umbilical	97	8 (8.3%)	0.41	6.2
<b>Monti</b>				
Traditional	<b>146</b>			
Non-umbilical	96	14 (14.6%)	0.03	8.4
Umbilical	50	6 (12.0%)	0.19	9.9
Spiral	<b>150</b>			
Non-umbilical	94	11 (11.7%)	0.13	4.8
Umbilical	56	18 (32.1%)	<0.001	9.0

# Subfascial Revisions



Number at risk:

Appendicovesicotomy	215	116	41	17	7	0
Spiral umbilical Monti	56	36	16	0	0	0
All other Monti channels	240	134	63	5	0	0



# What do we tell the families about risk?


Subfascial Revision = Major Surgery

	<u>5years</u>	<u>10years</u>
Appendicovesicostomy	6.4%	8.6%
Monti Channels	12.9%	15.5%
Spiral to Umbilicus	27.9%	32.3%

**Majority of revisions occur in first 5 years**

# BLADDER AUGMENTATION

## Common Sense Follow Up Evaluation



### **Stones:**

- Yearly RBUS and KUB

### **Recurring UTI:**

- RBUS/KUB, review CIC technique, ?cystoscopy

### **Metabolic:**

- Yearly CBC, BMP, Cystatin C, B12 yearly after 5 years
- ? DEXA scan




### **Cancer Surveillance:**

- High Risk: Yearly cystoscopy, cytology starting 5 yrs. (?)
- Low Risk: Evaluate aggressively for hematuria, recurrent UTI, pain, abnormal X-ray

# Ileal Chimney

- Drains continuously
- Protects kidneys
- Appliance works well

For patients that loose Bladder priveleges:



# Spina Bifida Urologic Care

## What Have We Learned?


- Our patients want to be continent, **but not until later**
- Our patients want to be continent of stool, **earlier**
- Our patients **survive into adulthood**, and need care
- Our patients are **sexual adults**, want help early
- Our patients are **fertile**, and need our help then too
- Our patients are still teaching us medical lessons.....








# Probability of Reaugmentation –



Number at risk

recon = 0 57 40 24 7 0

# Need for Family Surgery...



Francis Collins, MD, PhD  
Director, Human Genome Project

- Prepare for dramatic change
- Your path will not be smooth.
  - Build a strong foundation up front (train for opportunity)
  - Be a responsible skeptic
- Clarify your definition of success.
  - Allow it to change over time
- Define **resume** virtues vs. *eulogy* virtues

# It We Are Going To Augment the Bladder What Is the Cost To the Patient?

- Metabolic
  - Acidosis; B12 deficiency; Bone Density
- Mucus
- UTI
- Bladder Stones
- Bladder Perforation
- Malignancy risk

# BLADDER AUGMENTATION

Indy 500 (patients)

<u>Segment</u>	<u># pts</u>	<u>%</u>
Ileum	297	60
Sigmoid	85	17
Stomach	38	8
Cecal	46	9
Ileum + sig.	8	1.6
Ureter	8	1.6
Ureter +ileum	3	.6
Stomach + bowel	7	1.4




# BLADDER AUGMENTATION

## Indy 500

- **Bowel Obstruction**
- **3.2% (16 patients)**
- **Mean time from surgery = 51 months**
  - **7 < 2 months**
  - **9 > 12 months**

# Risk per Segment

## Bowel Obstruction




# **BLADDER AUGMENTATION**

## **Major Complications**

- **Two potentially lethal complications:**
  - **Perforation**
  - **Malignancy**

# BLADDER AUGMENTATION PERFORATION



**Indy 500**

**41 patients - 53 ruptures**

# SPONTANEOUS BLADDER PERFORATION

500 Patients

## Perforation Risk:

Sigmoid 16/84 (19%)

Ileum 23/297 (7%)

Gastric 2/44 (5%)



Cecal 2/38 (4%)

Mean time aug-to-perf: 46 months

**Overall Risk 43/500 (8.2%); 9 had > 1 perf.**



# CT Cystogram for Rupture/Leakage



**45 ruptured bladder augmentations in >900 pts. (5%)**


**2 most critical findings: symptoms, increase fluid**

**Karmazyn et al J Ped Urol, 2015**

**Poor pt. compliance, abuse increases risk (Husmann, 2016)**

# Risk with Bladder Neck Surgery

## Perforation




# BLADDER AUGMENTATION

## Perforation

**CIC Catheterizable  
channel  
- 4.4%**

**CIC Native urethra  
- 12.2%**



# Management of Bladder Perforation

- Laparotomy, bladder closure, drainage
- Rarely percutaneous drainage and bladder drainage
  - Still need externalization of VP shunt

# 483 PTS. with AUGMENTATIONS

260 > 10 year F/U

## 3 patients presented with metastatic TCC

- Age at Augmentation

- 8, 20, and 24 yrs

- Age at Diagnosis

- 29, 37, and 44 y/o respectively

- mean time from augmentation to TCC = 19 years

- Type of Augmentation

- ileocecal (2)      cecal (1)



# BLADDER AUGMENTATION

- 4.6% malignancy with augment; 2.6% risk CIC no augment
- 153 patients with augment; 1:1 Control group on CIC only.
- **NGB - 97 pts**
  - 2% (2 / 97) TCC s/p augment; 3% (3/97) on CIC no aug
  - > 2PPD tobacco use > 25 yrs.
- **Exstrophy – 39 pts**
  - 8% (3 / 39) adenocarcinoma s/p augment
  - 3% (1/38) adenocarcinoma on CIC without augmentation
- **PUV – 18 pts**
  - 12% (2 / 18) CA s/p augment; 0/18 on CIC
  - both had renal transplant
  - immunosuppressed - viral cystitis increase risk

# Nephrogenic Adenoma – Benign Tumor



# BLADDER AUGMENTATION

## Recommendations – IU Current

### Routine Follow-Up For Cancer Screening


- Renal bladder ultrasound yearly
- KUB yearly
- Cytology:
  - yearly beginning at 5 years (**unhelpful**)
- Cystoscopy:
  - yearly beginning at 7-10 years in high risk (?)
  - hematuria, recurrent UTI, pain, US mass

# BLADDER STONES


## #1 Problem

- Not mentioned in early series
- Hendren - 1990 18%
- Hirst - 1991 18%
- Blyth - 1992 30%
- Palmer - 1993 52%
- Boston - 1998 13%
- **Indiana - 2006 15%**

# Stone Risk with Catheterizable Channel











**10-50% Risk**



**Not all stones  
Created equal...**

# Bladder Stones – Percutaneous Removal







# Stone Recurrence in Augmented Bladder


To determine if recurrence correlated with treatment modality:

1. Open vs. endoscopic vs. percutaneous
2. Stone fragmentation

Retrospective review of 107 patients treated for bladder stones at our institution (1981-2013)


# Results

**Stones recurred in 51 (47.7%) patients  
at median 9.5 years (range 3mo.-14.7 years)**





# High Volume Lavage



# AUGMENTING THE AUGMENTED BLADDER

## Significant Contractions

### 19/323 (5.9%)


Initial Bowel Segment	No. Total	(%)
Sigmoid	12/87	(13.8%)
Gastric	4/39	(10.3%)
Ileocecal	1/48	(2.1%)
Ileal	2/145	(1.4%)

Indy 500 Update:  
- 9.4% (47pts) of 500 pts.

*Pope, et al  
J. Urol, 1998*

Calin Mark PhD MD  
Urodynamics UR

203008764



MRN

3e:1

203008764



Calin Mark PhD MD  
Urodynamics UR

203008764

RILEY Study Date: 11/3/2005

Study Time: 12:58:33 PM

MRN:



# Serum B12 Following Augmentation Metabolic Consequences

## Ileal Enterocystoplasty and B12 Deficiency in Pediatric Patients

David H. Rosenbaum,\* Mark P. Cain, Martin Kaefer, Kirstan K. Meldrum, Shelly J. King,  
Rosalia Misseri and Richard C. Rink

*From the Division of Pediatric Urology, Riley Hospital for Children, Indianapolis, Indiana*

**Purpose:** Vitamin B12 deficiency is a feared complication of enterocystoplasty but it has never been demonstrated in pediatric patients who have undergone ileal enterocystoplasty. We reviewed our series of more than 500 bladder augmentations in an attempt to define the timing and risk of vitamin B12 deficiency in pediatric patients after bladder augmentation.

**Materials and Methods:** From October 2004 to present we obtained serum B12 values in patients who had undergone bladder augmentation at our institution. We looked at patients who had undergone ileal enterocystoplasty and who were 18 years or younger at the time of augmentation. Any B12 value that was obtained while on any form of B12 supplementation was excluded. These criteria resulted in 79 patients with 105 B12 values. B12 values of 200 pg/ml or less were considered "low," and values between 201 and 300 pg/ml were considered "low-normal."


**Results:** There was a statistically significant correlation between followup time and serum B12 ( $p = 0.0001$ ). The probability of low B12 increased as followup time increased ( $p = 0.007$ ), as did the probability of low-normal B12 ( $p = 0.005$ ). Starting at 7 years postoperatively 6 of 29 patients (21%) had low B12 values, while 12 of 29 (41%) had low-normal values.

**Conclusions:** Pediatric patients who have undergone ileal enterocystoplasty are at risk for development of vitamin B12 deficiency. These patients are at the highest risk beginning at 7 years postoperatively, and the risk increases with time. We recommend an annual serum B12 value in children beginning at 5 years following bladder augmentation.

*Key Words: vitamin B 12 deficiency, urinary bladder, pediatrics*

TABLE 1. Statistical data on total B12 values


	Age at Augmentation (mos)	Mos Followup	B12 (pg/ml)
Mean	101.5	88	448
SD	46.8	48.3	261
SE	5.3	5.4	29.4
Min	24	29	71
Max	215	239	1,337
Median	88	72	340





# RESULTS




## Initial Vitamin B<sub>12</sub> Levels After Oral Supplementation



# Long term outcomes of Oral B12 – POOR COMPLIANCE.....

- 25/36 patients had documented follow-up with multiple serum B12 levels after initiation of oral therapy (mean F/U 49 months)
- Only 9/25 patients (36%) had normal serum B12 levels on most recent follow-up
- Need to consider injection therapy for low B12?

# Still The Gold Standard (For Some Patients)



# What you need to remember:

- Yearly follow up
  - BMP, CBC, B12, KUB, RBUS
- Prompt evaluation for gross hematuria, abdominal pain
  - Cystoscopy, CT cystogram
- Catheterization problems are an emergency
- Pregnancy and delivery will require your presence
- Involve your pediatric/transitional urologist




Gracias!





# 1. Congenital Localized Sclerotic and Social





# Riley Pediatric Urology Team 2018




Mission: Willa, Bial, NP, T, J, W, NP, J, B, MD

# Historical Surgical Pathway to Continence

Evolution of continence:

- Intermittent catheterization
- **Bladder outlet resistance**
- Bladder augmentation

- 
- Mitrofanoff procedure
  - MACE procedure



# Ideal BN Procedure: Does Not Exist

- Dry at 3-4 hours +/- CIC
- No change in bladder capacity/compliance
  - ie avoids need for augmentation
- Preserve kidneys, ie allows leakage at high bladder P
- Allow easy CIC per urethra
- Long term durability
- Technically easy to perform

# Long Term Fate of the Bladder after Bladder Neck Procedure

**Retrospective review: Bladder neck surgery without augmentation with greater than 4 years follow-up (1997 – 2008)**

***Primary outcome: incidence of augmentation***

***Secondary outcome: predictors of augmentation***

**Urodynamics reviewed and analyzed**

**Bladder capacity, DLPP, and compliance/detrusor pressure**

**29 patients met inclusion criteria, average follow-up 8.9 years  
(4.0 – 13.3)**

**16 (55%) avoided augment at last follow-up**


**13 (45%) underwent delayed augmentation**




# Results: Time to Augmentation


- Average Time to Augment: 3 years
- Indications for Augment
  - New/Worsening Incontinence: 5
  - New VUR/Hydronephrosis: 5
  - New Renal Scarring: 2
  - Small bladder capacity: 6
  - Poor compliance: 7
- All patients with 2+ indications for augmentation
- No significant difference between groups regarding: age, sex, ambulatory status or VP shunt.

# Probability of Remaining Augment Free






# 2016 UDS Post-DND Data





# 2016: UDS Post BNR +





# Surgery, and Life in General.....

We shall not cease from exploration<sup>[SEP]</sup>  
And the end of all our exploring<sup>[SEP]</sup>  
Will be to arrive where we started<sup>[SEP]</sup>  
And know the place for the first time.

TS Eliot

The Four Quartets





# Catheterizable Channels

## Indiana Experience 1990-2013

Appendicovesicostomy	215
----------------------	-----

Monti ileovesicostomy	296
-----------------------	-----

Continent Vesicostomy	<u>33</u>
-----------------------	-----------

<b><u>Total Urinary Channels:</u></b>	<b><u>544</u></b>
---------------------------------------	-------------------

MACE	415
------	-----

<b><u>Total Cath Channels:</u></b>	<b><u>959</u></b>
------------------------------------	-------------------

# Mitrofanoff Principle

- Mobilization of bladder
- Mobilization of channel pedicle
- Minimize extravesical channel length
- Wide spatulation of channel on both ends
- Wide skin stomal flap
- Secure bladder to posterior abdominal wall
- Cath channel multiple times during procedure

**Short, Straight, Supple**

(any supple tube)

- **Appendix / Ureter 1980**
- Fallopian tube
- Vas deferens
- Stomach 1991
- **Bladder 1992**
- Yang 1993
- Tapered ileum 1994
- Prepuce 1995
- **Monti – Yang 1993, 1997**
- **Spiral Monti 1000**



# Appendicovesicostomy vs. Monti

0022-5347/99/1625-1749/0

THE JOURNAL OF UROLOGY

Copyright © 1999 by AMERICAN UROLOGICAL ASSOCIATION, INC.

Vol. 162, 1749-1752, November 1999

Printed in U.S.A.

## APPENDICOVESICOSTOMY AND NEWER ALTERNATIVES FOR THE MITROFANOFF PROCEDURE: RESULTS IN THE LAST 100 PATIENTS AT RILEY CHILDREN'S HOSPITAL

MARK P. CAIN, ANTHONY J. CASALE, SHELLY J. KING AND RICHARD C. RINK

*From the Department of Urology, James Whitcomb Riley Hospital for Children, Indiana University Medical Center, Indianapolis, Indiana*

**100 pts. : 57 Apv, 21 Monti, 21 CV**

**- 98% continence, 12% stomal stenosis**

**- 20 secondary procedures**



**12/57 Apv (21%) F/U 31 mos**

**2/21 Monti (10%) F/U 9 mos**

# The David Bloom Principle:

“Mark, that is all very good, but show me a study with at least 100 patients and at least 10 years of continuous follow up, and then you will have made a real statement (ie become an expert)....”

# APPENDICOVESICOSTOMY






# Mitrofanoff Procedure



# APPENDICULECTOMY





## Disadvantages

- Fatty mesentery
- Short mesentery
- Used for MACE
- Prior appendectomy
- Not useable







# CONTINENT VESICOSTOMY





# CONTINENT VESICOSTOMY





# CONTINENT VESICOSTOMY

**continence  
100%**



**Stomal stenosis  
45%**

# CONTINENT VESICOSTOMY


31 patients

- 17 RLQ, 7 umbo., 7 neoumbo
- 31/31 (100%) continent
- 14/31 ( 45%) stomal stenosis
- 20/31 ( 65%) still using CV



# Monti – Yang Tube

1997 -1993






# Early Data – Monti Procedure

<u>Study</u>	<u>n</u>	<u>F/U</u>	<u>Continent</u>	<u>Stenosis</u>
Gerharz	16	4.1	81%	n/a
Cain	21	8.5	95%	4 %
Castellan	25	13	93%	0 %
Mcandrew	21	34	n/a	24%
Narayanaswamy	25	25	88%	16%

# Mitrofanoff Procedure Monti Channel






**What if you need a longer channel?**






# Double Monti





# SPINAL MOUTH



Casale

Urol 1000




# Mitrofanoff Procedure



# Catheterizable Channels: Complications

- Stomal Stenosis
- Angulation of Channel
- Leakage
- Trauma
- Obliteration
- Abscess
- Polyp



**Short, Straight  
Supple, Secure**

# Appendicovesicostomy vs. Monti

<b>Study</b>	<b>n</b>	<b>F/U</b>	<b>Continent</b>	<b>Stenosis</b>
Multiple Authors (Appendix)	408	33mo	94%	14.7%

<i>Indiana</i>	<i>198</i>	<i>39 mo</i>	<i>96%</i>	<i>11.6%</i>
<i>Monti</i>				

<i>Indiana</i>	<i>111</i>	<i>62 mo</i>	<i>96 %</i>	<i>12%</i>
<i>Appendix</i>				



# APV and Monti: Channel Complications

## Riley Series >500 Procedures

Stomal stenosis	34 (60.7%)
Channel angulation/elongation	9 (16.1%)
Tissue overgrowth/granulation	6 (10.7%)
Prolapse	3 (5.4%)
Polyp	3 (5.4%)
Peristomal abscess	1 (1.8%)
<b>TOTAL</b>	<b>56</b>

# Mitrofanoff Stoma






# Appendicovesicostomy vs. Monti

	<u>Appendix</u>	<u>Monti</u>
• Follow up	62 months	39 mos
• Early complic.	4%	3.5%
• Skin revision	12%	11.6%
• Bladder revision	5%	8.5%
• Tube replacement	4%	1%
• Cath prob/endoscopy	5%	5.5%
• Leakage	4% (25%)	4% (25%)



# Mitrofanoff Channels

Stomal




Subfascial



# Szymanski, J Ped Urol, 2015


Channel type and stomal location	Number	Number of first subfascial revisions	P-value	Median follow-up (years)
<b>APV</b>	<b>215</b>			
Non-umbilical	118	6 (5.1%)	reference	5.4
Umbilical	97	8 (8.3%)	0.41	6.2
<b>Monti</b>				
<b>Traditional</b>	<b>146</b>			
Non-umbilical	96	14 (14.6%)	0.03	8.4
Umbilical	50	6 (12.0%)	0.19	9.9
<b>Spiral</b>	<b>150</b>			
Non-umbilical	94	11 (11.7%)	0.13	4.8

# Subfascial Revisions




Number at risk:


Appendicovesicotomy	215	116	41	17	7	0
Spiral umbilical Monti	56	36	16	0	0	0




# Current technique











**3 institutions.**

**675 urinary channels**

**Does Anterior Position Matter?**

**Riley (458), Argentina (178), Chile (39)**

**Male 53.8%**


**VPS 49.7%**

**Median age at surgery: 8.8 years old**

**Median follow-up: 6.0 years**


**\*results reliable up to 10 years**

# Appendicovesicostomy (n=387)




121	67	26	11	5	0
266	135	25	2	1	0

# Traditional Monti (n=235)





# Spiral umbilical Monti (n=53)





# Open Mitrofanoff

- No difference for anterior vs posterior Mitrofanoff channel with open technique
- Continence rate 95-96%, with "good" bladder
- Revision rate approximately 25%
- Anterior placed channel using minimally invasive technique should duplicate open experience
  - IN EXPERIENCED HANDS


# What you need to remember:

- Yearly follow up
  - BMP, CBC, B12, KUB, RBUS
- Prompt evaluation for gross hematuria, acute abdominal pain
  - Cystoscopy, CT cystogram
- Catheterization problems are an emergency
- Pregnancy may require your presence
- Involve your pediatric urologist


If you learn nothing else from this  
lecture, read these books..







# Subfascial Revisions



Number at risk:

Appendicovesicotomy	215	116	41	17	7	0
Spiral umbilical Monti	56	36	16	0	0	0

**PEDIATRIC  
UROLOGY**

- Congenital anatomy
- Patient-centered relationship
- Integrative care
- Initial reconstructive techniques

***UROLOGIC  
CONGENITALISM***

**ADULT  
UROLOGY**

- Post-pubertal expertise  
aka “adult care”
- Adult urologic screening
- Adult physiology
- Fertility
- Sexual function